Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress

Endocrinology and Metabolism, Supplement

Volumn 3, Issue 3, 1996, Pages 149-166

  Thornalley, Paul J ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW;

EID: 0029743039     PISSN: 1074939X     EISSN: 20935978     Source Type: Journal    
DOI: None     Document Type: Review

References (173)

1. Hodge JE. The Amadori rearrangement. Adv. Carbohydrate Chem. 1955; 10: 169-205.
2. Ledl F, Schleicher E. New aspects of the Maillard reaction in foods and in the human body. Agnew. Chem. Int. Ed. Eng. 1990; 29: 565-594.
3. Njoroge FG, Monnier VM. The chemistry of the Maillard reaction under physiological conditions: A review. In: Baynes JW, Monnier VM, editors. The Maillard reaction in aging, diabetes and nutrition. New York: A. R. Liss, 1989: 85-109.
4. Ahmed MU, Thorpe SR, Baynes JW. Identification of Ntcarboxymethyl-lysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem. 1986; 261: 4889-4894.
5. Ahmed MU, Dünn JA, Walla MD, Thorpe SR, Baynes JW. Oxidative degradation of glucose adducts to protein. (Formation of 3-(/Ve-lysino)-lactic acid from model compounds and glycated proteins. J. Biol. Chem. 1988; 263: 8816-8821.
6. Sell DR, Monnier VM. Structure elucidation of a senescence crosslink from human extracellular matrix. Implication of pentoses in the aging process. J. Biol. Chem. 1989; 264: 21597-21602.
7. Portero-Otin M, Nagaraj RH, Monnier VM. Chromatographie evidence for pyrraline formation during protein glycation in w'froand in vivo. Biochim. Biophys. Acta 1994; 1247: 74-80.
8. Henle T, Walter A, Haebner R, Klostermeryer H. Detection and Identification of a Protein-Bound Imidazolone resulting from the Reaction of Arginine Residues and Methylglyoxal. Z. Lebansm. Unters. Forsch. 1994; 199: 55-58.
9. Hayase F, Konishi Y, Kato H. Identification of the modified structure of arginine residues in proteins with 3-deoxyglucosone, a Maillard reaction intermediate. Biosci. Biotech. Biochem. 1995; 59: 1407-1411.
10. Kato H, Shin DB, Hayase F. 3-Deoxyglucosone crosslinks proteins under physiological conditions. Agric. Biol. Chem. 1987; 51-.2009-2011.
11. Kawakishi S, Tsunehiro J, Uchida K. Autoxidative degradation of Amadori compounds in the presence of copper ion. Carbohydr. Res. 1991; 211: 167-171.
12. Zyzak DV, Richardson JM, Thorpe SR, Baynes JW. Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch. Biochem. Biophys. 1995; 316: 547-554.
13. Papoulis A, AI-Abed Y, Bucala R. Identification of N2(1-carboxyethyDguanine (CEG) as a guanine advanced glycosylation endproduct. Biochemistry 1995; 34: 648655.
14. Vaca CE, Hou S. Development of a 32P-Post labelling method for the analysis of 2'-deoxyguanosine-3'-monophosphate and DNA adducts of Methylglyoxal. Carcinogenesis 1994; 15: 1887-1894.
15. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA 1993; 90: 6434-6438.
16. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 1995; 276: 10017-10025.
17. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. A/e-(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-10878.
18. Horiuchi S, Araki N, Morino Y. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. J. Biol. Chem. 1991; 266: 7329-7332.
19. Taneda S, Monnier VM. ELISA of pentosidine, an ad-vanced glycation end-product, in biological specimens. Clin. Chem. 1994; 40: 1766-1773.
20. Radoff S, Makita Z, Vlassara H. Radioreceptor assay for advanced glycosylation end products. Diabetes 1991; 40: 1731-1738.
21. Vishwanath V, Frank KE, Elmmets CA, Dauchot PJ, Monnier VM. Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications. Diabetes 1986; 35: 916-921.
22. Lapolla S, Poli T, Gerhardinger C, Fedele D, Crepaldi G, Chiarello D, Ghezzo E, Traldi P. Parent ion spectroscopy in the identification of advanced glycation products. Biomed. Environm. Mass. Spectrometry 1989; 18: 713-718.
23. Lapolla A, Gerhardinger C, Baldo L, Fedele D, Keane A, Seraglia R, Catinella S, Traldi P. A study on in vitro glycation processes by matrix-assisted laser desorption ionization mass spectrometry. Biochim. Biophys. Acta 1993; 1225: 33-38.
24. Lapolla A, Fedele D, Seraglia R, Catinella S, Baldo L, Aronica R, Traldi P. A new effective method for the evaluation of glycated intact plasma proteins in diabetic subjects. Diabetologia 1995; 38: 1076-1081.
25. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products, in vivo. J. Biol. Chem. 1992; 267: 5133-5138.
26. Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD. Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol. Dial. Transplant. 1995; 10: 657-664.
27. McCance DR, Dyer DG, Dünn JA, Baiue KE, Thorpe SR, Baynes JW, Lyons TJ. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 1993; 91: 2470-2478.
28. Dyer DG, Dünn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance PR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 1993; 91: 2463-2469.
29. Monnier VM, Viswanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. New. Engl. J. Med. 1986; 314: 403-408.
30. Kohn RR, Cerami A, Monnier VM. Collagen aging in vitro by nonenzymatic glycosylation and browning. Diabetes 1984; 33: 57-59.
31. Lee WK, Bell J, Kilpatrick E, Hayes M, Lindop GBM, Dominiczak MH. Collagen linked fluorescence in human atherosclerotic plaques. Atherosclerosis 1993; 98: 219227.
32. Westwood ME, Thornalley PJ. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J. Prot. Chem. 1995; 14: 359-372.
33. Dünn JA, Ahmed MU, Murtiashoq MH, Richardson JM, Walla MD, Thorpe SR, Baynes JW. Reaction of ascorbate with lysine and protein under autoxidising conditions: formation of /VE(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990; 29: 10964-10970.
34. Smith PR, Thornalley PJ. Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. (Studies with the model fructosamine, A/-(1-deoxy-D-fructose-1-yl)hippuryl-lysine). Eur. J. Biochem. 1992; 210: 729-739.
35. Dünn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: Age-dependent accumulation of Af(carboxymethyl)lysine in lens proteins. Biochemistry 1989; 28: 9464-9468.
36. Dünn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of /N/E-(carboxymethyl)lysine and A/E-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 1991; 30: 1205-1210.
37. Liardon R, de Weck-Gaudard D, Philipossian G, Finot P. Identification of /Ve-carboxymethyllysine: a new Maillard reaction product, in rat urine. J. Agric. Food. Chem. 1987; 35: 427-431.
38. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992; 258: 651-653.
39. Wolffenbuttel BHR, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996; 347: 513-515.
40. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinckjohnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylation end-products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824829.
41. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM, Aging of Proteins: Immunological detection of a Glucose-derived Pyrrole Formed during Maillard Reaction in Vivo. J. Biol. Chem. 1989; 263: 3758-3763.
42. Smith PR, Somani HH,Thornalley PJ, Benn J, Sonksen PH. Evidence against the formation of 2-amino-6-(2-formyl5-hydroxymethyl-1-yl)-hexanoic acid Cpyrraline') as an early-stage product of advanced glycation end product in non-enzymic protein glycation. Clin. Sci. 1993; 84: 87-93.
43. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991; 266: 11654-11660.
44. Takahashi M, Ohishi T, Aoshima H, Kawana K, Kushida K, Inoue T, Horiuchi K. The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia 1993; 36: 664-667.
45. Lyons TJ, Silvestri G, Dünn JA, Dyer DG, Baynes JW. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes 1991; 40: 1010-1015.
46. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographie quantitation of plasma and erythrocyte pentosidine in diabetic and urémie subjects. Diabetes 1992; 41: 153-159.
47. Lo TWC, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and Modification of Proteins by Methylglyoxal under Physiological Conditions A Kinetic and Mechanistic Study with A/a-Acetylarginine, /va-Acetylcysteine, and A/a-Acetyllysine, and Bovine serum albumin. J. Biol. Chem. 1994; 269: 32299-32305.
48. Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur. J. Biochem. 1993; 212: 101-105.
49. Pompliano DL, Peyman A, Knowles JR. Stabilization of a reaction intermediate as a catalytic device: Definition of the functional role of the flexible loop in triosephosphate isomerase. Biochemistry 1990; 29: 3186-3194.
50. Koop DR, Casazza JP. Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. J. Biol. Chem. 1985; 260: 13607-13612.
51. Lyles GA, Chalmers J. The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amino oxidase in human umbilical artery. Biochem. Pharmacol. 1992; 43: 1409-1414.
52. Thornalley PJ. Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem. J. 1988; 254 751-755.
53. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. 1994; 87: 21-29.
54. Phillips SA, Mirrlees D, Thornalley PJ. Modification of the glyoxalase system in streptozotocin-induced diabetic rats; effect of the aldose reductase inhibitor Statil. Biochem. Pharmacol. 1993; 46: 805-811.
55. Thornalley PJ. The glyoxalase system in health and disease. Molec. Aspects Med. 1993; 14: 287-371.
56. Ratliff DM, Vander Jagt DJ, Eaton RP, Vander Jagt DL. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II-a clinical research center study. J. Clin. Endocrinol. Metab. 1996; 81: 488-492.
57. Ueno H, Segawa T, Hasegawa T, Nakamuro K, Maeda H. Subchronic oral toxicity of glyoxal via drinking water in rats. Fundam. Appl. Toxicol. 1991; 16: 763-772.
58. Brinkmann E, Wells-Knecht KJ, Thorpe SR, Baynes JW. Characterization of an imidazolium compound formed by reaction of methylglyoxal and /V-hippuryllysine. J. Chem. Soc. Perkin. Trans. 1995; 1: 2817-2818.
59. Shapiro R, Cohen Bl, Shiuey S-J, Maurer H. On the reaction of guanine with glyoxal, pyruvaldehyde and ketoxal and the structure of the acylguanines. A new synthesis of N2-alkylguanines. Biochemistry 1969; 8: 238245.
60. Chen H-JC, Cerami A. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J. Carbohydr. Chem. 1993; 12: 731-742.
61. Kang Y, Edwards LG, Thornalley PJ. Effect of methylglyoxal on cell growth: induction of apoptosis in human leukaemia 60 cells but not in concanavalin A-stimulated peripheral human lymphocytes. Leuk. Res. 1996; 20: 397405.
62. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. J. Am. Chem. Soc. 1995; 34: 3702-3709.
63. Loidl-Stahlhofen A, Spiteller G. a-Hydroxyaldehydes, products of lipid peroxidation. Biochem. Biophys. Acta 1994; 1211: 156-160.
64. Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J. Biol. Chem. 1984; 259: 3812-3817.
65. Shinoda T, Hayase F, Van Chuyen N, Kalo H. Uptake of proteins modified with 3-deoxyglucosone, a Maillard reaction intermediate, by the type I macrophage scavenger receptor. Biosci. Biotech. Biochem. 1993; 57: 18261831.
66. Lo TWC, Selwood T, Thornalley PJ. Reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem. Pharmacol. 1994; 48: 18651870.
67. Krantz S, Brandt R, Gromoll B. Binding sites for shortterm glycated albumin on peritoneal cells of the rat. Biochem. Biophys. Acta 1993; 1177 15-24.
68. Salazar R, Brandt R, Krantz S. Expression of fructosyllysine receptors on human monocytes and monocyte-like cell lines. Biochim. Biophys. Acta 1995; 1266: 57-63.
69. Krantz S, Salazar R, Brandt R, Kellermann J, Lottspeich F. Purification and partial amino acid sequencing of a fructosyllysine-specific binding protein from cell membranes of the monocyte-like cell line U937. Biochim. Biophys. Acta 1995; 1266: 109-112.
70. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Endocytic uptake of non-enzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde modified proteins. J. Biol. Chem. 1988; 268:14189-14825.
71. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino S. Scavenger receptor of human monocytic leukemia cell line (THP-1) and murine macrophages for non-enzymatically glycosylated proteins. Biochim. Biophys. Acta 1989; 986: 18-26.
72. Westwood ME, McLellan AC, Thornalley PJ. Receptormediated endocytic uptake of methylglyoxal-modified serum albumin. Competition with advanced glycation endproduct-modified serum albumin at the advanced glycation endproduct receptor. J. Biol. Chem. 1994; 269: 32293-32298.
73. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, Horiuchi S. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end-products of the Maillard reaction. Eur. J. Biochem. 1995; 230:408-415.
74. Ashkenas J, Penman M, Vasile E, Freeman M, Krieger M. Structures and high and low affinity binding properties of murine type I and type II macrophage scavenger receptors. J. Lipid Res. 1993; 34: 983-1000.
75. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan YE, Tsang TE, Stern D. Isolation and characterization of two binding proteins for advanced glycosylation endproducts from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992; 267: 1498714997.
76. Vissing H, Aagaard L, Tommerup N, Boel E. Localization of the human gene for advanced glycosylation end productspecific receptor (AGER) to chromosome 6p 21.3. Genomics 1994; 24: 606-608.
77. Sakata N, Meng J, Jimi S, Takebayashi S. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis 1995; 116: 63-75.
78. Abordo EA, Argirov OK, Thornalley PJ. Human serum albumin minimally-modified by methylglyoxal but not by glucose-derived advanced glycation endproducts induced the synthesis and secretion of tumour necrosis factor-a (TNFa) by human monocytic THP-1 cells in vitro. () Diabetes 1996, 45 (suppl 2): 129A.
79. Shaw SM, Crabbe MJC. Non-specific binding of advanced glycosylation endproducts to macrophages outweighs specific receptor-mediated interactions. Biochem. J. 1994; 304: 121-129.
80. Westwood ME, Thornalley PJ. Induction of synthesis and secretion of interleukin 1β in the human monocytic leukaemia THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. Immunol. Lett. 1996, in press.
81. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pas A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodelling. Science 1988; 240: 1546-1548.
82. Lovett DH, Ryan JL, Sterzel RB. Stimulation of rat mesangial cell-proliferation by macrophage interleukin-1. J. Immunol. 1983; 131: 2830-2836.
83. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular-matrix production in mouse mesangial cells by advanced glycation endproducts is mediated via platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 1992; 89: 2873-2877.
84. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I (IGF-1) in human monocytes by advanced glycosylation end product-modified proteins. J. Clin. Invest. 1992; 90: 439-446.
85. Wang JM, Walter S, Mantovani A. Re-evaluation of the chemotactic activity of tumour necrosis factor for monocytes. Immunology 1990; 71: 364-367.
86. Nathan C, Sanchez E. Tumour necrosis factor and CD11/ CD18 (b2) integrins act synergistically to lower cAMP in human neutrophils. J. Cell. Biol. 1990; 111: 2171-2181.
87. Westwood ME, Thornalley PJ. Cytokine synthesis and secretion induced by methylglyoxal-modified proteins. Diabetic Med. 1995; 12: S49 (abstract).
88. de Villiers WJS, Fraser IP, Hughes DA, Doyle AG, Gordon S. Macrophage-Colony-Stimulating Factor Selectively En-hances Macrophage Scavenger Receptor Expression and Function. J. Exp. Med. 1994; 180: 705-709.
89. Guilbert LJ, Winkler-Lowen B, Smith A, Branch DR, GarciaLloret M. Analysis of the synergistic stimulation factor (SCF-1 ) and tumour necrosis factor a (TIMFa). J. Leukocyte Biol. 1993; 54: 65-72.
90. Kimball ES, Kovacs E, Clark MC, Schneider CR. Activation of cytokine production and adhesion molecule expression in THP-1 myelomonocytic cells by macrophage colonystimulating factor in combination with interferon-gamma. J. Leukocyte Biol. 1995; 58: 585-594.
91. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Molecular Medicine 1995; 1: 447-456.
92. Yui S, Sasaki T, Araki N, Horiuchi S, Yamasaki M. Induction of macrophage growth by advanced glycation end products of the Maillard reaction. J. Immunol. 1994; 152: 1943-1949.
93. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, Sehajpal P, Vlasara H. Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-gamma: role in tissue remodeling. J. Exp. Med. 1993; 178: 2165-2172.
94. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Mavab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990; 344: 254-257.
95. Wang J, Wang S, Lu Y, Weng Y, Gown AM. GM-CSF and M-CSF expression is associated with macrophage proliferation in progressing and regressing rabbit atheromatous lesions. Exp. Mol. Pathol. 1994; 61: 109-118.
96. Diamond JR, Ding G, Frye J, Diamond IP. Glomerular macrophages and the mesangial proliferative response in the experimental nephrotic syndrome. Am. J. Pathol. 1992; 141:887-894.
97. Limb GA, Earley 0, Jones SE, Leroy F, Chignell AH, Dumonde DC. Expression of messenger RNA coding for TNF-a, IL-1β and IL-6 by cells infiltrating retinal membranes. Graeffes Arch. Clin. Exp. Ophthalmol. 1994; 232: 646-651.
98. Jaffe GJ, Roberts WL, Wong HL, Yurochko AD, Cianciolo GJ. Monocyte-induced cytokine expression in cultured human retinal pigment epithelial cells. Exp. Eye Res. 1995; 60: 533-543.
99. Palkama T. Induction of interleukin-1 production by ligands binding to the scavenger receptor in human monocytes and the THP-1 cell line. Immunology 1991; 74: 432-438.
100. Kirstein M, Brett J, Radoff S,0gawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of PDGF: role in vacular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA 1980; 87: 9010-9014.
101. Tezuka M, Koyama N, Morisaki N, Salto Y, Yoshida S, Araki N, Horiuchi S. Angiogenic effects of enhanced glycation end products of the Maillard reaction on cultured human umbilical chord vein endothelial cells. Biochem. Biophys. Res. Commun. 1993; 193: 674-680.
102. Bucala R, Tracey K, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J. Clin. Invest. 1991; 87: 432-438.
103. Baynes JW. Role of oxidative stress in the development of complications in diabetes. Diabetes 1991; 40: 405-412.
104. Van Dam PS, Van Asbeck BS, Erkelns DW, Marx JJM, Gispen W-H, Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab. Rev. 1995; 11: 181-192.
105. Hunt JV, Wolff SP. Oxidative glycation and free-radical production - a causal mechanism of diabetic com-plications. Free Radical Res. Commun. 1991; 12-13: 11S123.
106. Wolff SP. Diabetes mellitus and free radicals. Br. Med. Bull. 1993; 49: 642-652.
107. Van SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou SY, Pinsky D, Stern D. Enhanced Cellular Oxidant stress by the Interaction of Advanced Glycation End Products with their Receptors/Binding Proteins. J. Biol. Chem. 1994; 269: 9889-9897.
108. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori 0, Zoukourian C, Capron L, Chappey 0, Van DS, Brett J, Guillausseau PJ, Stern D. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surfaceassociated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA 1994; 91: 7724-7746.
109. Thornalley PJ. Modification of the glyoxalase system in human red-blood cells by glucose in vitro. Biochem. J. 1988; 354: 751-755.
110. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995; 44:1054-1058.
111. Jain SK, McVie R, Duett J, Herbst JJ. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 1989; 38: 1539-1543.
112. Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GDO, Small M. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992; 41: 909-913.
113. Altomare E, Vendemiale G, Chicco D, Procacci V, Cirelli F. Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabète & Métabolisme 1992; 18: 264271.
114. Griesmacher A, Kindhauser M, Ändert SE, Schreiner W, Toma C, Knoebl P, Pietschmann P, Prager R, Schnack C, Schernthaner G, Mueller MM. Enhanced serum levels of thiobarbituric acid-relative substances in diabetes mellitus. Am. J. Med. 1995; 98: 469-475.
115. Wieruszwysocka B, Wysocki H, Byks H, Zozulinska D, Wykretowicz A, Kazmierczak M. Metabolic control quality and free-radical activity in diabetic-patients. Diabetes Res. Clin. Practice 1995; 27: 193-197.
116. Sinclair AJ, Girling AJ, Gray L, Lunec J, Barnett AH. An investigation of the relationship between free radical activity and vitamin C metabolism in elderly diabetic subjects with retinopathy. Gerontology 1992; 38:268-274.
117. Saul G, Ames B. Measuring oxidative damage in humans: relation to cancer and aging. In: Bartsch H, Hemminski K, O'Neil IL, editors, Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention. Lyon, 1988: 407-424.
118. Dandona P, Thusa K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet 1996; 347: 444-445.
119. Kitahara M, Eyre HJ, Lynch RE, Rallison ML, Hill HR. Metabolic activity of diabetics' monocytes. Diabetes 1980; 29: 251-256.
120. Costagliola C. Oxidative state of glutathione in red blood cells and plasma of diabetic patients: in vitro and in vivo study. Clin. Physiol. Biochem. 1990; 8: 204-210.
121. Murakami K, Kondo T, Ohtsuka Y, Fujiwara Y, Shimada M, Kawakami Y. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism 1989; 38: 753-758.
122. Bono A, Caimi G, Catania A, Sarno A, Pandolfo L. Red cell peroxide peroxide metabolism in diabetes mellitus. Horm. Met. Res. 1987; 19: 264-266.
123. Jain SK, McVie R. Effect of glycaemic control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism 1994; 43: 306-309.
124. Som S, Basu S, Mukherjee D, Deb S, Choudhury PR, Muckerjee S, Choudhury SN, Chatterjee S, Chatterjee IB. Ascorbic acid metabolism in diabetes mellitus. Metabolism 1981; 30: 572-577.
125. Stankova L, Riddle M, Larned J, Burry K, Menashe D, Hart J, Bigley R. Plasma ascorbate concentrations and blood cells dehydroascorbate transport in patients with diabetes mellitus. Metabolism 1984; 33: 347-353.
126. Yue DK, McLennan S, Fisher E, Hefferman S, Capogreco C, Ross GR, Turtle JR. Ascorbic acid metabolism and the polyol pathway in diabetes. Diabetes 1989; 38: 257-261.
127. Sinclair AJ, Girling AJ, Gray L, Le Guen C, Lunée J, Barnett AH. Disturbed handling of ascorbic acid in diabetic patients with and without microangiopathy during high dose ascorbate supplementation. Diabetologia 1991; 34: 171-175.
128. Paolisso G, D'Amore A, Di Maro G, Galzerano D, Tesauro P, Varricchio M, Donofrio F. Evidence for a relationship between free radicals and insulin action in the elderly. Diabete Metab. 1993; 42: 659-663.
129. Jennings PE, McLaren M, Scott NA, Saniabadi AR, Belch JJF. The relationship of oxidative stress to thrombotic tendency in type-1 diabetic patients with retinopathy. Diabetic Medicine 1991; 8: 860-865.
130. Petersen A, Szwergold BS, Kappler F, Weingarten M, Brow TW. Identification of sorbitol 3-phosphate and fructose 3phosphate in normal and diabetic human erythrocytes. J. Biol. Chem. 1990; 265: 17424-17427.
131. Scionti L, Puxeddu A, Calabrese G, Gatteschi C, De Angelis M, Bolli G, Compagnucci P, Calafiore R, Brunetti P. Erythrocyte concentrations of glycolytic phosphorylated intermediates and adenosine nucleotides in subjects with diabetes mellitus. Horm. Metabol. Res. 1982; 14: 233-236.
132. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes-induced glomerular dysfunction - links to a more reduced cytosolic ratio of NADH/NAD +. Kidney International 1992; 41: 778-788.
133. Azevedo MS, Raposo J, Fontes G, Manso C. Oxygen radical generation by Maillard compounds, J. Diabetic Complications 1988; 2: 19-21.
134. Cillery P, Monboisse JC, Maquart FX, Borel JP. Glycation of proteins as a source of Superoxide. Diabete & Mé tabolisme 1996; 14: 25-30.
135. Sakurai T, Sugioka K, Nakano M. 02 Generated lipid peroxidation during the oxidation of a glycated polypeptide, glycated polylysine, in the presence of iron-ADP. Biochim. Biophys. Acta 1990; 1043: 27-33.
136. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherosclerosis in diabetes. Biochem. Biophys. Res. Commun. 1990; 173: 932-939.
137. Bannister JV, Bellavite P, Serra MC, Thornalley PJ, Rossi F. An EPR study of the production of Superoxide radicals by the neutrophil NADPH oxidase. FEBS Lett. 1982; 145: 323-326.
138. Bannister JV, Bellavite P, Davoli A, Thornalley PJ, Rossi F. Production of hydroxyl radicals from neutrophilic NADPH oxidase catalysed by transferrin. FEBS Lett. 1982; 150: 300-302.
139. Wolff SP, Dean RT. Glucose autoxidation and protein modification; the potential role of autoxidative glycosylation in diabetes. Biochem. J. 1987; 245: 243-250.
140. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes-mellitus and aging. Free Radicals Biol. Med. 1991; 10: 339-352.
141. Wells-Knecht MC, Thorpe SR, Baynes JW. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995; 34: 15134-15141.
142. Thornalley PJ, McLellen AC, Lo TWC, Benn J, Sonksen PH. Increased Concentrations of Glyoxal and Methylglyoxal in blood samples of IDDM Patients, relative to Age- and Sex-matched Normal Healthy Human Subjects. () Diabetes 1996, 45 (Suppl. 2): 270A.
143. Donnini D, Zambito AM, Perrella G, Amesi-lmpiombato FS, Curcio F. Glucose may induce cell death through a free radical-mediated mechanism. Biochem. Biophys. Res. Commun. 1996; 219: 412-417.
144. Curcio F, Ceriello A. Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In Vitro Cell Dev. Biol. 1992; 28A: 787-790.
145. Curcio F, Pegoraro I, Dello Russo P, Falleti E, Parella G, Ceriello A. SOD and GSH inhibit the high glucose-indiced oxidative damage and the PDGF increased secretion in cultured human endothelial cells. Thrombosis and Haemostasis 1995; 74: 969-973.
146. Gonzalez AM, Sochor M, Hothersall JS, McLean P. Effect of aldose reductase inhibitor (Sorbinil) on integration of polyol pathway, pentose-phosphate pathway and glycolytic route in diabetic lens. Diabetes 1986; 35: 1200-1205.
147. Trocino RA, Akazawa S, Ishibashi M, Matsumoto K, Matsuo H, Yamamoto H, Goto S, Urata Y, Kondo T, Nagataki S. Significance of glutathione depletion and oxidative stress in early embryogenesis in glucose-induced rat embryo culture. Diabetes 1995; 44: 992-998.
148. Travis SF, Morrison AD, Clements RSJ, Wingrad AI, Oski FA. Metabolism of glucose in human erythrocytes by the polyol pathway. J. Clin. Invest. 1972; 50: 2104-2112.
149. 202 in human umbilical vein endothelial cells cultured in high glucose medium. Diabetologia 1994; 37: 264-269.
150. Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, Pirisi M, Falleti E, Bartoli E. Hyperglycaemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44: 924-928.
151. Minhas HS, Thornalley PJ. Comparison of the delivery of reduced glutathione into P388D, cells by reduced glutathione and its mono- and di-ethyl ester derivatives. Biochem. Pharmacol. 1995; 49: 1475-1482.
152. Hirsch J, Petrakova E, Feather MS. The reaction of some dicarbonyl sugars with aminoguanidine. Carbohydr. Res. 1992; 232: 125-130.
153. Paolisso G, D'Amore A, Galzerano D, Balbi V, Giuliano D, Varricchio M, Donofrio F. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993; 16: 1433-1437.
154. Paolisso G, Di Maro G, Pizza G, Damore A, Sgamato S, Varricchio M, Donofrio F. Plasma GSH/GSSG affects glucose homeostasis in healthy subjects and non-insulindependent diabetics. Am. J. Physiol. 1992; 263: E435E440.
155. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biol. Med. 1995; 19: 227-250.
156. Ziegler D, Hanefeld M, Ruhnau KJ, Meibner HP, Lobisch M, Schutte K, Gries FA. Treatment of symptomatic diabetic peripheral neoropathy with the anti-oxidant oe-lipoic acid. Diabetologia 1995; 38: 1425-1433.
157. Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittock DA, Tritschler H, Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-1167.
158. Gabbay KH. Hyperglycaemia, polyol metabolism, and complications of diabetes mellitus. Annu. Rev. Med. 1975; 26: 521-536.
159. Vlassara H, Brownlee H, Cerami A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromulecules. Proc. Natl. Acad. Sci. USA 1985; 82: 5588-5592.
160. SkolnikEY,Yang Z, MakitaZ, RadoffS, Kirstein M,Vlassara H. Human and rat mesangial cell receptors for glucosemodified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 1991; 174: 931-939.
161. Hammes H-P, Strodter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Seconary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995; 38: 656-660.
162. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguinadine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992; 35: 946-950.
163. Vlassara H, Fun H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc. Natl. Acad. Sci. USA 1992; 89: 12043-12047.
164. Zimmerman GA, Meistrell M, Bloom 0, Cockcroft KM, Bianchi M, Risucci D, Broome J, Farmer P, Cerami A, Vlassara H, Tracey KJ. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc. Natl. Acad. Sci. USA 1995; 92: 3744-3748.
165. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632.
166. Soulis-Liparota T, Cooper M, Papazoglou DX, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial cell expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334.
167. Tilton RG, Chang K, Hasan KS, Smith SR, Petrach JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221-232.
168. Young IS, Täte S, Lightbody JH, McMaster D, Trimble ER. The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin-induced diabetic rat. Free Radical Biol. Med. 1955; 18: 833-840.
169. Bravenboer B, Kappelle AC, Hamers FPT, van Buren T, Erkele DW. Potential use of glutathione for the streptozotocin-induced diabetic rat. Diabetologica 1992; 35: 813-817.
170. Sochor M, Kunijara S, McLean P. The effect of aldose reductase inhibitor Statil (IC1128436) on the glucose overutilization in kidney of diabetic rats. Biochem. Pharmacol. 1988; 37: 3349-3356.
171. Malone Jl, Leavengood H, Petersen MJ, O'Brien MM, Page MG. Red blood cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulindependent diabetic subjects. Diabetes 1984; 33: 45-49.
172. Tomlinson DR, Moriarty RJ, Mayer JH. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Diabetes 1984; 33: 470-176.
173. Boel E, Selmer J, Flodgaard HJ, Jensen T. Diabetic complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? J. Diabetes and its Complications 1995; 9: 104129.